PODCAST (ENGLISCH)Sign up to Get FREE Steroids, SARMS, Peptides eBooks
Many people not only struggle to lose weight but also have trouble when trying to quit smoking. Glücklicherweise, a single drug called Acomplia could solve both problems.
There’s a long list of foods that bodybuilders and other athletes try to avoid. Among these are fast foods, fattening snacks, and sugary drinks as long-term or excessive consumption of these kinds of foods can leave a person overweight and forced to deal with multiple health problems. But eating stuff like this is often a nasty habit that some athletes just can’t seem to shake no matter how hard they try.
An even nastier habit that athletes can fall into is smoking which might be even more detrimental to one’s physical goals. Smoking leads to increased blood pressure and heart rate as well as various lung diseases and none of this adds up to bettering one’s body. Offensichtlich, the combination of fatty foods and smoking equals a decrease in one’s athletic performance.
So athletes and people alike often need to turn to various drugs to curb the disastrous effects that such habits can create. leider, this usually means that they have to take both a dieting drug and a smoking cessation drug separately in order to fulfill both needs. But imagine if there was a drug that could satisfy the two demands. No longer would people be required to take multiple medications in order to keep their weight down and their nicotine cravings in check.
You may not have to simply imagine this anymore though as the company Sanofi-Aventis believes that they may have developed a single drug that can act as both a dieting agent and smoking cessation agent. Its name is Acomplia and it has been the buzz of the pharmaceutical community as of late. This is mainly because it has been touted as more than just another diet pill with its proposed benefits to those who are trying to stop smoking.
The drug is said to work by blocking the receptors of a substance called cannabinoid 1. Found prominently in fat tissue throughout the body, cannabinoid 1 (CB 1) is the substance that is most responsible for stimulating hunger and other cravings in the brain. Since Acomplia, a.k.a. Rimonabant, works to suppress CB1 from causing cravings in the brain, it is also believed to help prevent people from overeating or smoking heavily.
Results from previous clinical trials have backed up many of the claims made by Sanofi-Aventis about its possible blockbuster drug Acomplia. In a couple of trials called RIO: EUROPE and RIO: NORTH AMERICA, almost one-third of the patients participating in the two year procedure had a weight reduction of 10% by the end of the trials. Waist Circumference was also toned down by a whopping 3 inches in both of the studies as well.
And these aren’t the only benefits that patients of the trials experienced either as all of those taking part in the clinical studies had higher levels of the good cholesterol, HDL. The positives didn’t stop here either as everyone seemed to show a decrease in triglycerides (sehr hoher Lautstärke kann zu Herzerkrankungen führen) und eine verbesserte Empfindlichkeit gegenüber Insulin.
But the results of the trials weren’t all rosy though as there were some reported side effects too. Some of the more mild ones were nausea, Gelenkschmerzen, schwindel, diarrhea, and vomiting. Hingegen, these effects were reported to have decreased during the second year of use with the drug. The major side effect came in the form of psychiatric problems, especially depression, stemming from discontinued use of the drug. It was even reported that some of the patients’ weights increased along with their psychiatric problems after their use of Rimonabant ended.
These side effects certainly remain question marks as to how well the drug will sell but its approval as a diet aid is no longer in question as Acomplia is already being sold in the United Kingdom. It has also received approval from the Food and Drug Administration for the sale in the United States and will be hitting the shelves sometime in the near future (possibly under the name Zimulti in the U.S. as opposed to its brand name of Acomplia in Europe).
While Acomplia’s ride to approval as a diet drug may have been fairly easy, as far as getting by the FDA’s rigorous standards goes, its approval as a smoking cessation aid has been met with nothing but controversy. The drug that was once dubbed as being able to double the odds of helping people to put down cigars and cigarettes somehow failed to live up to its own boasts in the eyes of the FDA as they rejected its use as a smoking cessation aid.
Sanofi-Aventis was shocked to say the least after the rejection of their prized Rimonabant as a smoking suppressor. Two trials failed to sway the FDA’s opinion of Acomplia and the decision was made in February to put a halt to one half of the dream drug’s marketability. If Sanofi-Aventis hopes for Rimonabant to ever become a smoking cessation aid, they will have to conduct another trial that can prove once and for all that the drug is an effective aid to those wishing to break the habit.
Even though its approval for smoking cessation is currently in limbo, Rimonabant hasn’t lost its momentum in the media and continues to create excitement among those wishing to shed some pounds. Acomplia has already been said to help those with diabetes in addition to keeping people’s weight down while they are on anti-depressants.
Außerdem, the latest news on the drug is that it may play a role in fighting breast cancer in women. This was reported after some tests were performed on mice by Italian researchers that revealed Acomplia inhibited the growth of a highly dangerous form of breast cancer called MBA-MB-231.
Plus the price of Rimonabant is currently lower in the United Kingdom than what was expected, providing an even bigger push to Sanofi-Aventis’ goal of selling 5 billion dollars-worth of Acomplia/Zimulti each year. It has been selling for right around 55 pounds in Britain (über $100 US-) and is actually one of the cheapest diet drugs on the market as of now.
It’s still up in the air as to whether Rimonabant will hit the United States market under the name Acomplia or Zimulti but it is already clear that the drug’s arrival is anxiously awaited. New benefits stemming from Rimonabant’s use are constantly popping up in the headlines everyday it seems and the prospect of losing 10% of one’s body weight in one year already has people rushing to buy it illegally online.
Despite the jury still being out on its smoking cessation benefits, many people already swear by Acomplia and the crowd just keeps growing. Is Rimonabant the end to the world’s (especially America’s) fight against obesity? The jury is still out on this as well but I think many people across the globe are willing to give it a try.
[sc:signoff-std]
|
Und Sie wichtige Funktionen wie bekommen:
 Lesen Sie mehr.... oder Bestellen Sie Ihre Mitgliedschaft! |
ein 5000 PM-Postfach - anstatt 50, 
Sign up to Get FREE Steroids, SARMS, Peptides eBooks
